Pharmafile Logo

Inizio Unveils Next-Generation Hub Services at Asembia 2026, Setting a New Standard in Patient Access

May 5, 2026 | Pharma, healthcare, patient access 

Integrated capabilities combining advanced analytics, pharmacy, and specialized talent to improve access, affordability, and adherence

- PMLiVE

Inizio announced the official launch of its fully integrated, end-to-end Hub Services, a cornerstone of its market-leading Patient Solutions offering. Delivered by Inizio Engage, the Inizio business unit specializing in patient engagement and support, this next-generation solution addresses the growing complexity of patient access, reimbursement, and adherence, while enabling clients to partner with a more agile, strategic, and outcome-driven organization.

As life sciences organizations navigate an increasingly dynamic policy and payer landscape, and higher expectations from patients, the need for more connected, patient-centric support models has never been greater. “Inizio Engage’s evolved Hub Services introduces a next-generation approach, integrating human expertise, intelligent technology, and pharmacy capabilities, supported by advanced analytics to simplify and accelerate the path to therapy,” said Ryan Quigley, CEO, Inizio. “This launch represents another opportunity for Inizio to lead the way as the global Intelligent Commercialization partner, bringing together insight, innovation, and execution to deliver more coordinated, patient-centered solutions for our clients.”

Read full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

How we elevated HCP market research engagement and insights using AI avatars for an immersive experience

Our client required an effective strategy for promoting discussions about self-paid vaccines with healthcare professionals (HCPs) during patient consultations. The conventional method of conducting market research would typically only deliver…

How we provided comprehensive real-world patient data for PAH using Therapy Watch, our syndicated market tracking solution

PAH is a specific type of pulmonary hypertension, which is a rare condition treated primarily in specialized centers. Our client needed to gain a comprehensive understanding of PAH patients, such…

Latest European developments and new talent at Research Partnership

Angela Duffy has been appointed as Managing Director for our European based ad hoc research teams. Angela has been an integral part of Research Partnership for 19 years, witnessing its…

New syndicated report – Living with Ulcerative Colitis 2024

Living with Ulcerative Colitis (UC) is a new syndicated patient report that presents valuable insights into the unmet needs and the burden experienced by patients living with UC. The report…

Webcast: AI in MRX: Harnessing the power of AI + people

Artificial intelligence (AI) in market research has surged in recent years, with a flow of innovative tools and techniques which have the potential to revolutionize the landscape. But to unlock…

Navigating challenges of MedTech research with rare-disease patients

Authored by: Tom Donnelly, MedTech Director and Amanda Pirraglia, Associate Director. Published in Quirk’s Magazine.

Product launch: What market research when?

Get the insights you need, when you need them, for your product launch planning

Therapy Watch launches new tracker covering Alzheimer’s Disease

The new Therapy Watch Alzheimer’s Disease tracker has recently launched in Germany, Japan and the US, with planned expansion into the remaining key European markets throughout 2024.

Therapy Watch launches new tracker covering pulmonary arterial hypertension (PAH)

Therapy Watch Pulmonary Arterial Hypertension (PAH) is launching in the US market, with expansion into other geographies including Europe in 2024.